Denosumab News and Research

RSS
Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone.
Results of PCF funded study could impact the standard of care for prostate cancer patients

Results of PCF funded study could impact the standard of care for prostate cancer patients

Denosumab reduces fractures in postmenopausal women with osteoporosis

Denosumab reduces fractures in postmenopausal women with osteoporosis

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Amgen and GlaxoSmithKline to collaborate on Denosumab for postmenopausal osteoporosis

Amgen and GlaxoSmithKline to collaborate on Denosumab for postmenopausal osteoporosis

Amgen announces positive results for Denosumab postmenopausal osteoporosis trial

Amgen announces positive results for Denosumab postmenopausal osteoporosis trial

Study looks at denosumab in preventing bone loss caused by aromatase inhibitors

Study looks at denosumab in preventing bone loss caused by aromatase inhibitors

Bone erosion reduced by denosumab

Bone erosion reduced by denosumab

Low bone density improved with jabs twice a year

Low bone density improved with jabs twice a year